- Global Pharma News & Resources

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

Lonza Group AG / Key word(s): Personnel
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
12.09.2022 / 07:00 CET/CEST

  • Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee
  • Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams
  • Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who will continue to serve as President of Biologics

Basel, Switzerland, 12 September 2022 – Lonza today announced that its Board of Directors has approved the appointment of Daniel Palmacci as President of its Cell & Gene Division. The appointment will be effective from 1 November 2022. Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonza’s Biologics Division.

Daniel joins Lonza Group with more than two decades of experience in the pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare. He also brings a wealth of international experience, having previously held roles in Switzerland, Germany, Italy, India, Brazil, France and the US.

Most recently Daniel served as Senior Vice President, Global Head of Technical Operations and Executive Committee member at MorphoSys, a commercial-stage biopharmaceutical company. In this role, he transformed the Technical Operations function with a focus on improving its commercialization capabilities. He also oversaw the digitalization and AI strategy of MorphoSys, with a view to accelerating clinical development.

Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division. The appointment builds on the recent achievements and ongoing growth of both Divisions under Jean-Christophe’s leadership since January 2021. The expanded Executive Committee structure provides a dedicated President for each of Lonza’s four Divisions, thereby maximizing the growth potential of each area of the business.

Albert M. Baehny, Chairman, Lonza, commented: “We extend a warm welcome to Daniel as he joins the Lonza Group Executive Committee and takes on the leadership of Cell & Gene. Daniel is well placed to lead our Cell & Gene Division, as a seasoned leader in the pharmaceuticals industry with a proven track record working with novel breakthrough therapies.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Daniel’s expertise in leading cross-functional teams will take our diverse offerings within Cell & Gene into a new stage of growth and development. I extend my gratitude to Jean-Christophe for his dedicated leadership of both our Biologics and Cell & Gene Divisions since January 2021. With Jean-Christophe now solely dedicated to leading our Biologics offering, we are positioned to consolidate our leading market position and maintain our focus on long-term success across both Divisions.” 

Daniel holds a Masters in Chemistry and Process Engineering from Technical University Berlin, Germany. He is relocating from Munich (DE) to Basel (CH), where Lonza is headquartered.

Learn more about Lonza’s Cell & Gene offering here:

About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283

Lyle Wheeler
Investor Relations
Lonza Group Ltd
Tel +41 79 154 9522

End of Media Release

Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Phone: +4161 316 81 11
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1439795

End of News EQS News Service

Editor Details

Last Updated: 12-Sep-2022